Sodium phosphate p-32 - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for sodium phosphate p-32 and what is the scope of patent protection?
Sodium phosphate p-32
is the generic ingredient in two branded drugs marketed by Bracco and Mallinckrodt, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.Summary for sodium phosphate p-32
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 8 |
Clinical Trials: | 173 |
Patent Applications: | 4 |
Formulation / Manufacturing: | see details |
DailyMed Link: | sodium phosphate p-32 at DailyMed |
Recent Clinical Trials for sodium phosphate p-32
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Collegium Medicum w Bydgoszczy | Phase 3 |
Khyber Medical College, Peshawar | Phase 4 |
Odense University Hospital, Department of Nephrology | Phase 4 |
US Patents and Regulatory Information for sodium phosphate p-32
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt | SODIUM PHOSPHATE P 32 | sodium phosphate p-32 | SOLUTION;INJECTION, ORAL | 011777-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bracco | PHOSPHOTOPE | sodium phosphate p-32 | SOLUTION;INJECTION, ORAL | 010927-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Mallinckrodt | SODIUM PHOSPHATE P 32 | sodium phosphate p-32 | SOLUTION;INJECTION, ORAL | 011777-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |